Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes

Endocrine Practice

Volumn 13, Issue 7, 2007, Pages 721-725

  Bulchandani, Deepti G ^a   Konrady, Tara ^b   Hamburg, Mitchell S ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b ST LUKE S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; ASIAN AMERICAN; BLOOD; BODY WEIGHT; CAUCASIAN; COMPARATIVE STUDY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN RESISTANCE; MALE; MIDDLE AGED; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; RETROSPECTIVE STUDY;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN AMERICANS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PATIENT SATISFACTION; RETROSPECTIVE STUDIES;

EID: 38949190747     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.7.721     Document Type: Article

References (21)

1. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2005.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
4. American Association of Diabetes Educators. Intensive diabetes management: implications of the DCCT and UKPDS. Diabetes Educ. 2002;28:735-740.
5. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005;28:15-19.
6. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593-598.
7. Davidson JK, DeBra DW. Immunologic insulin resistance. Diabetes. 1978;27:307-318.
8. Nathan DM, Axelrod L, Flier JS, Carr DB. U-500 insulin in the treatment of antibody-mediated insulin resistance. Ann Intern Med. 1981;94:653-656.
9. Hatipoglu B, Soni S, Espinosa V. Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocr Pract. 2006;12:542-544.
10. Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract. 2006;12:251-256.
11. Baumann G, Drobny EC. Enhanced efficacy of U-500 insulin in the treatment of insulin resistance caused by target tissue insensitivity. Am J Med. 1984;76:529-532.
12. Fain JA. Insulin resistance and the use of U-500 insulin: a case report. Diabetes Educ. 1987;13:386-389.
13. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Longterm results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-B29.
14. Pfützner A, Berger S, Spinas G. Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus [article in German]. Schweiz Med Wochenschr. 2000;130:1854-1861.
15. Bretzel RG. Intensive insulin regimens: evidence for benefit. Int J Obes Relat Metab Disord. 2004;28(Suppl 2):S8-S13.
16. Hirsch IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl 5A):21S-26S.
17. Knee TS, Seidensticker DF, Walton JL, Solberg LM, Lasseter DH. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003;9:181-186.
18. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568-1573.
19. Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care. 2006;29:2175-2176.
20. Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients [erratum in Diabetes Care. 2007;30:455]. Diabetes Care. 2006;29:2504-2505.
21. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598-2603.